Dexrazoxane
Dexrazoxane is a pharmaceutical drug with 27 clinical trials. Currently 10 active trials ongoing. Historical success rate of 56.3%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
9
Early Stage
11
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
56.3%
9 of 16 finished
43.8%
7 ended early
10
trials recruiting
27
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
Clinical Trials (27)
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Dexrazoxane to Protect Against Hemorrhagic STEMI
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 27